Navigation Links
Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
Date:7/13/2011

INDIANAPOLIS, July 13, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that it has made a charitable contribution to the Patient Advocate Foundation (PAF). The donation will enable expansion of the foundation's patient services programs, including Case Management and Co-Pay Relief (CPR) Programs in support of a new fund for patients with nonsquamous non-small cell lung cancer (NSCLC), the most common form of lung cancer.  

PAF is a national, non-profit organization that seeks to safeguard patients through effective mediation, assuring access to care, and preservation of employment and financial stability, relative to their diagnosis of life-threatening or debilitating diseases. The CPR Program provides direct financial support for co-payments for medicines to insured patients, including Medicare beneficiaries who financially and medically qualify.

Since the program's inception in April 2004, CPR has distributed more than $120 million in assistance to more than 46,000 patients who were unable to afford their co-payments for medications. PAF also has a long-standing history of service to the lung cancer community, having the oldest lung cancer fund in the U.S. In the 12 months ending March 31, 2011, PAF received requests from more than 8,000 lung cancer patients, providers and/or caregivers, but, given the size of the fund, was only able to assist less than six percent of those patients.

"We understand that treating cancer involves more than delivering innovative medicines," said Sue Mahony, Ph.D., senior vice president and president, Lilly Oncology. "Aside from the health and emotional issues brought on by this devastating illness, there are often financial considerations. We applaud the Patient Advocate Foundation and hope with our assistance they can expand their vital services to even more patients," she added.

To request assistance from PAF, patients and physicians should contact their Co-Pay Relief Program by visiting www.copays.org or calling toll free (866) 512-3681.

Lilly Oncology has a tradition of supporting patients who cannot afford crucial medicines, with donations of cancer treatments valued at more than $16.3 million in 2010. PatientOne is a program that addresses financial and coverage issues for uninsured, insured, and underinsured patients who are candidates for Lilly oncology products. PatientOne supported more than 1,600 patients in 2010 and has recently expanded its eligibility requirements to include households with income up to 500 percent of the federal poverty level. To learn more about PatientOne, please visit www.LillyPatientOne.com.

About Non-Small Cell Lung Cancer (NSCLC)

Globally, lung cancer is the most common form of cancer and the biggest killer, causing 1.3 million cancer deaths annually.(1) About 85 – 90 percent of all lung cancers are NSCLC.(2)  The liver, bones and brain are potential targets if the cancerous cells enter the bloodstream.

NSCLC comprises a group of histologies or tumor types differentiated by cellular structure. Nonsquamous histology includes adenocarcinoma and large cell carcinoma, which account for more than half of all NSCLC diagnoses(3), as well as histologies classified as "other."

About Lilly Oncology

For more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer.  Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. To learn more about Lilly's commitment to cancer, please visit www.LillyOncology.com.  

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

P-LLY

(1) World Health Organization, Gender in Lung Cancer and Smoking Research, Department of Gender, Women and Health, 2003, http://www.who.int/gender/documents/en/lungcancerlow.pdf, (April 20, 2011).

(2) American Cancer Society, "What Is Non-Small Cell Lung Cancer?," December 16, 2010, American Cancer Society, http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer, (April 20, 2011).

(3) American Cancer Society, "What Is Non-Small Cell Lung Cancer?," October 20, 2009, American Cancer Society, http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer, (April 20, 2011).

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
2. Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System
3. Lilly Quality Leader Walsh Appointed to Companys Executive Committee
4. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
5. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
6. Lilly Declares Third-Quarter 2011 Dividend
7. Lilly for Better Health™ Launches Enhanced Multi-Channel Patient Education Platform
8. Synthes and Lilly Sign Development and Collaboration Agreement
9. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
10. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
11. Correction: Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
Breaking Medicine News(10 mins):